- Policy
- Korean-made COVID-19 treatment Rekirona distributed
- by Kim, Jung-Ju Feb 19, 2021 06:17am
- Celltrion has started supplying the first South Korean-made COVID-19 monoclonal antibody treatment Rekirona to healthcare institutes from Feb. 17. Rekirona is a first COVID-19 antibody treatment developed and manufactured in South Korea and it was approved by the Ministry of Food and Drug Safety (MFDS) with condition to further submit cli
- Policy
- The first generic of birth control pills Yaz is released
- by Lee, Tak-Sun Feb 19, 2021 06:17am
- The first generic for Yaz, a pre-contraceptive drug that has established itself in the market, and Duowell’s generic, a combination drug for hypertension and hyperlipidemia, was released. Generic for Yaz is the first with the same ingredients as the original, but in the case of Duowell’s generics, the same ingredient formulations are alr
- Policy
- AZ vaccine for 780,000 people will be inoculated
- by Lee, Tak-Sun Feb 18, 2021 06:28am
- AstraZeneca's COVID-19 vaccine, which starts vaccination on the 26th, received lot release from the MFDS. As a result, it is delivered from the factory and administered at each inoculation site. The lot-released vaccine is expected to be effective until June, and the KCDA plans to complete the vaccination until May. On the 17th, the MFD
- Policy
- AZ vaccine, the first inoculation in Korea from the 26th
- by Kim, Jung-Ju Feb 18, 2021 06:24am
- The domestic schedule for the COVID-19 vaccination treatment made by AstraZeneca has been confirmed. The government plans to fully implement vaccinations from the 26th, but plans to accumulate and determine additional clinical information for those over 65 years old people. Inoculation of AZ vaccine to the elderly over 65 is virtually wit
- Policy
- AstraZeneca Korea earns Consignment Business Authorization
- by Lee, Tak-Sun Feb 17, 2021 05:40am
- AstraZeneca Korea earned the seventh ‘Pharmaceutical Consignment Manufacturing Business Authorization’ in South Korea due to the COVID-19 vaccine manufactured by SK Bioscience. South Korea’s Ministry of Food and Drug Safety (MFDS) reported AstraZeneca Korea has been authorized for a pharmaceutical consignment manufacturing business o
- Policy
- Hanmi’s salt-modifying drug for Galvus, re-licensed
- by Lee, Tak-Sun Feb 17, 2021 05:39am
- Hanmi, which failed to enter the market for Vildagliptin through so-called split indications, has obtained item approval again. The MFDS approved Vildagle Tab 50mg (Vildagliptin HCl) by Hanmi on the 10th. It was licensed in January of last year, and Vildagle Tab 50mg, which was voluntarily withdrawn in July of that year. The withdrawn item
- Policy
- Novavax vaccine needed as AZ vaccine in 65 and up postponed
- by Lee, Tak-Sun Feb 16, 2021 06:08am
- The South Korean government seems to be considering on purchasing more doses of other COVID-19 vaccine options as the government has decided to hold off on inoculating the age group over 65 with AstraZeneca’s vaccine. Originally, the 65-and-up age group was supposed to be vaccinated within the first quarter, but it has been pushed to t
- Policy
- COVID-19 vaccine lot release to be authorized this week
- by Lee, Tak-Sun Feb 16, 2021 06:07am
- As a COVID-19 vaccine was authorized for the first time in South Korea, the lot release for AstraZeneca’s vaccine is expected to be granted this week. Although South Korea’s Ministry of Food and Drug Safety (MFDS) did not restrict inoculation on the age group over 65, the Korea Advisory Committee on Immunization Practices (KACIP) assoc
- Policy
- Fosamax 10mg·Pletaal OD Tab has been withdrawn
- by Lee, Tak-Sun Feb 16, 2021 06:07am
- MSD Korea's osteoporosis treatment Fosamax, and Otsuka Pharmaceutical's antiplatelet drug Pletaal OD Tab will be withdrawn from the Korean market due to poor performance. According to the MFDS on the 9th, as of the 8th, MSD Korea's Fosamax 10mg (Alendronic acid), Otsuka's Pletaal OD Tab 100mg, Pletaal OD Tab 50mg, and Pletaal Powder 20% (
- Policy
- The redemption of α-GPC benefits extended until March 15
- by Lee, Hye-Kyung Feb 15, 2021 06:17am
- The contract for reimbursement of benefits related to α-GPC, a brain function improvement drug, was extended until March 15th. The MOHW ordered The NHIS to extend the deadline for negotiations on the Choline alfoscerate formulation on the 10th. February 10, which ordered an extension of the negotiation period, marks the end of the first negotia
